News from grifols A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Apr 18, 2023, 10:30 ET Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines...

Nov 03, 2022, 09:00 ET Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1

AlphaID™ At Home, the company's first FDA clearance for direct-to-consumer use, enables U.S. adults to screen for their genetic risk of...

Oct 03, 2022, 12:52 ET Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and...

Sep 07, 2022, 12:06 ET Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this...

Jun 08, 2022, 05:00 ET Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening

Jun 08, 2022, 05:00 ET Le test Procleix Plasmodium de Grifols reçoit le marquage CE, une première pour un test de dépistage sanguin du paludisme

Jun 08, 2022, 05:00 ET Grifols Procleix Plasmodium Assay erhält als erster CE-Kennzeichnung fürMalaria-Blut-Screening

Jun 08, 2022, 05:00 ET Procleix Plasmodium Assay di Grifols riceve il marchio CE, il primo test per il rilevamento del parassita della malaria nel sangue

Apr 29, 2022, 14:00 ET Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United...

Mar 10, 2022, 05:00 ET XEMBIFY® de Grifols reçoit des approbations européennes, élargissant l'accès à des thérapies innovantes pour les patients

Mar 02, 2022, 09:00 ET Grifols partners with Feeding America® to help address hunger in the U.S.

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the...

Feb 24, 2022, 06:00 ET Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration...

Jan 04, 2022, 12:30 ET Grifols acquires its first plasma donation center in Canada

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today...

Oct 19, 2021, 11:18 ET Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record...

Jul 19, 2021, 06:00 ET Grifols étend son activité en Afrique en signant un accord pour la création d'une usine de fabrication de solutions intraveineuses au Nigeria

Jul 19, 2021, 06:00 ET Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria

- To be constructed by Grifols Engineering, a global standard-bearer in the development and building of advanced production facilities for the...

Jun 01, 2021, 10:30 ET Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure...

Apr 15, 2021, 09:00 ET Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100...

Apr 09, 2021, 10:30 ET Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United ...

Mar 25, 2021, 06:00 ET Les tests Procleix UltrioPlex E et Procleix Babesia de Grifols reçoivent le marquage CE

Mar 25, 2021, 06:00 ET Grifols Procleix UltrioPlex E and Procleix Babesia assays receive CE mark

Mar 25, 2021, 06:00 ET Grifols Procleix UltrioPlex E und Procleix Babesia Assays erhalten CE-Kennzeichnung

Mar 25, 2021, 06:00 ET I test Procleix UltrioPlex E e Procleix Babesia di Grifols hanno ottenuto il marchio CE

Mar 22, 2021, 09:00 ET Grifols installs first-ever DG Reader Net analyzer in North America

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of...